REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer-Response rate (RR), toxicity, and molecular analysis from phase II.
暂无分享，去创建一个
D. Smith | A. Wotherspoon | D. Cunningham | D. Ferry | S. Madhusudan | T. Crosby | G. Middleton | D. Gonzalez de Castro | I. Chau | Y. Barbáchano | A. Robinson | J. Waters | J. Wadsley | F. Coxon | A. Okines | C. Saffery | D. Swinson | S. Hulkki Wilson | M. Hall | L. Puckey